Palladium-Zeolite nanofiber as an effective recyclable catalyst membrane for water treatment.

Jungsu Choi,Sophia Chan,G. Yip,Hyun-Jae Joo,Heejae Yang,F. Ko

DOI: https://doi.org/10.1016/j.watres.2016.05.051

IF: 12.8

2016-09-15

Water Research

Abstract:

What problem does this paper attempt to address?

Antagonism of meta-chlorophenylpiperazine-induced inhibition of exploratory activity in an emergence procedure, the open field test, in rats

T. Meert,W. Melis,N. Aerts,G. Clincke

DOI: https://doi.org/10.1097/00008877-199708000-00008

1997-08-01

Behavioural Pharmacology

Abstract:The effects of meta-chlorophenylpiperazine (mCPP) were studied on exploratory behaviour in the open field test, using a procedure designed to evaluate the emergence of rats into a novel environment. mCPP reduced the exploratory activity in a dose-related manner after subcutaneous (s.c), intraperitoneal (i.p.) and intravenous (i.v.) administration. The inhibition was manifest in all the parameters used to quantify the exploration of the open field area. Additional neuroendocrine experiments in a parallel group of rats revealed a dose-related increase in plasma prolactin and ACTH levels after i.v. mCPP, pointing to a general state of arousal in these mCPP-treated animals. A number of 5-HT antagonists were tested for their ability to prevent or reverse the behavioural inhibition induced by an i.v. injection of 1.0 g/kg mCPP given 15 min before testing in the open field. The antagonists were injected s.c. or given orally at various time intervals before mCPP, or they were injected i.v. 10 min after mCPP. The lowest active doses for the attenuation of the mCPP-induced behavioural inhibition after s.c, oral and i.v. administration, respectively, were 0.04, 40 and 10 mg/kg for pizotifen; 0.16, 0.16 and 0.16 mg/kg for mianserin; 0.63, 0.16 and 0.16 mg/kg for methysergide, and 0.16, 2.5 and 2.5 mg/kg for ritanserin. The lowest active doses of mirtazapine after s.c. and i.v. treatment were 0.01 and 0.16 mg/kg. These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/5-HT2C antagonist ritanserin.
Pro-resolving lipid mediators are leads for resolution physiology

Charles N. Serhan

DOI: https://doi.org/10.1038/nature13479

IF: 64.8

2014-06-04

Nature

Abstract:Advances in our understanding of the mechanisms that bring about the resolution of acute inflammation have uncovered a new genus of pro-resolving lipid mediators that include the lipoxin, resolvin, protectin and maresin families, collectively called specialized pro-resolving mediators. Synthetic versions of these mediators have potent bioactions when administered in vivo. In animal experiments, the mediators evoke anti-inflammatory and novel pro-resolving mechanisms, and enhance microbial clearance. Although they have been identified in inflammation resolution, specialized pro-resolving mediators are conserved structures that also function in host defence, pain, organ protection and tissue remodelling. This Review covers the mechanisms of specialized pro-resolving mediators and omega-3 essential fatty acid pathways that could help us to understand their physiological functions.

multidisciplinary sciences
Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus

C N Serhan,N Chiang

DOI: https://doi.org/10.1038/sj.bjp.0707489

Abstract:Complete resolution of an acute inflammatory response and its return to homeostasis are essential for healthy tissues. Here, we overview ongoing efforts to characterize cellular and molecular mechanisms that govern the resolution of self-limited inflammation. Systematic temporal analyses of evolving inflammatory exudates using mediator lipidomics-informatics, proteomics, and cellular trafficking with murine resolving exudates demonstrate novel endogenous pathways of local-acting mediators that share both anti-inflammatory and pro-resolving properties. In murine systems, resolving-exudate leukocytes switch their phenotype to actively generate new families of mediators from major omega-3 fatty acids EPA and DHA termed resolvins and protectins. Recent advances on their biosynthesis and actions are reviewed with a focus on the E-series resolvins (RvE1, RvE2), D series resolvins (RvD1, RvD2) and the protectins including neuroprotectin D1/protectin D1 (NPD1/PD1) as well as their aspirin-triggered epimeric forms. Members of each new family demonstrate potent stereo-specific actions, joining the lipoxins as endogenous local signals that govern resolution and endogenous anti-inflammation mechanisms. In addition to their origins and roles in resolution biology in the immune system, recent findings indicate that these new mediator families also display potent protective actions in lung, kidney, and eye as well as enhance microbial clearance. Thus, these endogenous agonists of resolution pathways constitute a novel genus of chemical mediators that possess pro-resolving, anti-inflammatory, and antifibrotic as well as host-directed antimicrobial actions. These may be useful in the design of new therapeutics and treatments for diseases with the underlying trait of uncontrolled inflammation and redox organ stress.
Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators

Charles N. Serhan,Nan Chiang,Thomas E. Van Dyke

DOI: https://doi.org/10.1038/nri2294

IF: 108.555

2008-05-01

Nature Reviews Immunology

Abstract:Key PointsComplete resolution of an acute inflammatory response and its return to homeostasis are essential for healthy tissues. Resolution of acute inflammation is an active process, not just passive termination of inflammation.Novel families of lipid mediators are generated in inflammatory exudates during the resolution phase and they can promote and/or accelerate resolution. These mediators include the lipoxins, and the resolvins and (neuro)protectins, which are derived from the omega-3 essential fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).The pro-resolution lipid mediators are agonists of resolution, with multiple mechanisms of action at the tissue level: they 'stop' neutrophil and eosinophil infiltration; stimulate non-phlogistic recruitment of monocytes; enhance macrophage phagocytosis of apoptotic neutrophils; increase the exit of phagocytes from the inflammatory site to the lymphatics; and stimulate mucosal antimicrobial defence.Pro-resolution and anti-inflammation are not equivalent; pro-resolution programmes stimulate and activate endogenous pathways to terminate inflammation.Pro-resolution lipid mediators exert their protective activity at multiple levels in a range of cell types and in complex disease systems.Pro-resolution lipid mediators promote resolution of inflammation in oral, lung, ocular, kidney, neural and gastrointestinal inflammatory diseases, as well as in ischaemia–reperfusion injury and angiogenesis.

immunology
Nutritional modulation of the gut microbiota and immune system in preterm neonates susceptible to necrotizing enterocolitis.

R. Siggers,J. Siggers,T. Thymann,M. Boyé,P. Sangild

DOI: https://doi.org/10.1016/j.jnutbio.2010.08.002

2011-06-01

Abstract:
Development of synthetic lipoxin-A4 mimetics (sLXms): New avenues in the treatment of cardio-metabolic diseases

Monica de Gaetano

DOI: https://doi.org/10.1016/j.smim.2022.101699

Abstract:Resolution of inflammation is a complex, dynamic process consisting of several distinct processes, including inhibition of endothelial activation and leukocyte trafficking; promotion of inflammatory cell apoptosis and subsequent non-phlogistic scavenging and degradation; augmentation of pathogen phagocytosis; modulation of stromal cell phenotype coupled to the promotion of tissue regeneration and repair. Among these tightly regulated processes, the clearance and degradation of apoptotic cells without eliciting an inflammatory response is a crucial allostatic mechanism vital to developmental processes, host defence, and the effective resolution of inflammation. These efferocytic and subsequent effero-metabolism processes can be carried out by professional and non-professional phagocytes. Defective removal or inadequate processing of apoptotic cells leads to persistent unresolved inflammation, which may promote insidious pathologies including scarring, fibrosis, and eventual organ failure. In this manuscript, the well-established role of endothelial activation and leukocyte extravasation, as classical vascular targets of the 'inflammation pharmacology', will be briefly reviewed. The main focus of this work is to bring attention to a less explored aspect of the 'resolution pharmacology', aimed at tackling defective efferocytosis and inefficient effero-metabolism, as key targeted mechanisms to prevent or pre-empt vascular complications in cardio-metabolic diseases. Despite the use of gold standard lipid-lowering drugs or glucose-lowering drugs, none of them are able to tackle the so called residual inflammatory risk and/or the metabolic memory. In this review, the development of synthetic mimetics of endogenous mediators of inflammation is highlighted. Such molecules finely tune key components across the whole inflammatory process, amongst various other novel therapeutic paradigms that have emerged over the past decade, including anti-inflammatory therapy. More specifically, FPR2-agonists in general, and Lipoxin analogues in particular, greatly enhance the reprogramming and cross-talk between classical and non-classical innate immune cells, thus inducing both termination of the pro-inflammatory state as well as promoting the subsequent resolving phase, which represent pivotal mechanisms in inflammatory cardio-metabolic diseases.
Anti-inflammatory lipid mediators and insights into the resolution of inflammation

Toby Lawrence,Derek A. Willoughby,Derek W. Gilroy

DOI: https://doi.org/10.1038/nri915

IF: 108.555

2002-10-01

Nature Reviews Immunology

Abstract:Key Points The resolution of inflammation is a highly controlled and coordinated process that involves the suppression of pro-inflammatory gene expression, and of leukocyte migration and activation, followed by inflammatory-cell clearance by apoptosis and phagocytosis. New endogenous anti-inflammatory mediators, such as cyclopentenone prostaglandins (cyPGs) and lipoxins, might regulate the resolution of inflammation. Lipoxins are early braking signals for the inflammatory response; they inhibit neutrophil migration and activation, but promote the recruitment of monocytes and the phagocytic clearance of apoptotic cells by monocyte-derived macrophages. Cyclopentenone prostaglandins are potent suppressors of macrophage activation and specifically target the pro-inflammatory nuclear factor-κB (NF-κB) signalling pathways. NF-κB regulates the expression of pro-inflammatory and anti-apoptotic genes; therefore, cyPGs can mediate the resolution of inflammation through the suppression of pro-inflammatory gene expression and the promotion of leukocyte apoptosis. Both lipoxins and cyPGs have shown therapeutic promise in several animal models of inflammatory and autoimmune diseases. Therapeutic agents based on these new anti-inflammatory lipid mediators might offer a new approach to the treatment of chronic inflammatory diseases.

immunology
A signaling network map of Lipoxin (LXA4): an anti-inflammatory molecule

G. P. Suchitha,Rex Devasahayam Arokia Balaya,T. S. Keshava Prasad,Shobha Dagamajalu

DOI: https://doi.org/10.1007/s00011-024-01885-6

IF: 6.986

2024-04-27

Inflammation Research

Abstract:Lipoxins (LXs) are a class of endogenous bioactive lipid mediators that are involved in the regulation of inflammation. They exert immunomodulatory effects by regulating the behaviour of various immune cells, including neutrophils, macrophages, and T and B cells, by promoting the clearance of apoptotic neutrophils. This helps to dampen inflammation and promote tissue repair. LXs regulate the expression of many inflammatory genes by modulating the levels of transcription factors, such as nuclear factor κB (NF-κB), activator protein-1 (AP-1), nerve growth factor-regulated factor 1A binding protein 1 (NGF), and peroxisome proliferator activated receptor γ (PPAR-γ), which are elevated in various diseases, such as respiratory tract diseases, renal diseases, cancer, neurodegenerative diseases, and viral infections. Lipoxin-mediated signaling is involved in chronic inflammation, cancer, diabetes-associated kidney disease, lung injury, liver injury, endometriosis, respiratory tract diseases, neurodegenerative diseases, chronic cerebral hypoperfusion, and retinal degeneration. In this study, we systematically investigated the intricate network of lipoxin signaling by analyzing the relevant literature. The resulting map comprised 467 molecules categorized as activation/inhibition, enzyme catalysis, gene and protein expression, molecular associations, and translocation events. This map serves as a valuable resource for understanding the complexity of lipoxin signaling and its impact on various cellular functions.

immunology,cell biology
Resolution of Inflammation after Skeletal Muscle Ischemia–Reperfusion Injury: A Focus on the Lipid Mediators Lipoxins, Resolvins, Protectins and Maresins

Cindy Barnig,Gaetan Lutzweiler,Margherita Giannini,Anne Lejay,Anne-Laure Charles,Alain Meyer,Bernard Geny

DOI: https://doi.org/10.3390/antiox11061213

IF: 7.675

2022-06-21

Antioxidants

Abstract:Skeletal muscle ischemia reperfusion is very frequent in humans and results not only in muscle destruction but also in multi-organ failure and death via systemic effects related to inflammation and oxidative stress. In addition to overabundance of pro-inflammatory stimuli, excessive and uncontrolled inflammation can also result from defects in resolution signaling. Importantly, the resolution of inflammation is an active process also based on specific lipid mediators including lipoxins, resolvins and maresins that orchestrate the potential return to tissue homeostasis. Thus, lipid mediators have received growing attention since they dampen deleterious effects related to ischemia–reperfusion. For instance, the treatment of skeletal muscles with resolvins prior to ischemia decreases polymorphonuclear leukocyte (PMN) infiltration. Additionally, remote alterations in lungs or kidneys are reduced when enhancing lipid mediators' functions. Accordingly, lipoxins prevented oxidative-stress-mediated tissue injuries, macrophage polarization was modified and in mice lacking DRV2 receptors, ischemia/reperfusion resulted in excessive leukocyte accumulation. In this review, we first aimed to describe the inflammatory response during ischemia and reperfusion in skeletal muscle and then discuss recent discoveries in resolution pathways. We focused on the role of specialized pro-resolving mediators (SPMs) derived from polyunsaturated fatty acids (PUFAs) and their potential therapeutic applications.

biochemistry & molecular biology,chemistry, medicinal,food science & technology
Old and new generation lipid mediators in acute inflammation and resolution

Melanie J. Stables,Derek W. Gilroy

DOI: https://doi.org/10.1016/j.plipres.2010.07.005

IF: 14.673

2011-01-01

Progress in Lipid Research

Abstract:Originally regarded as just membrane constituents and energy storing molecules, lipids are now recognised as potent signalling molecules that regulate a multitude of cellular responses via receptor-mediated pathways, including cell growth and death, and inflammation/infection. Derived from polyunsaturated fatty acids (PUFAs), such as arachidonic acid (AA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA), each lipid displays unique properties, thus making their role in inflammation distinct from that of other lipids derived from the same PUFA. The diversity of their actions arises because such metabolites are synthesised via discrete enzymatic pathways and because they elicit their response via different receptors. This review will collate the bioactive lipid research to date and summarise the findings in terms of the major pathways involved in their biosynthesis and their role in inflammation and its resolution. It will include lipids derived from AA (prostanoids, leukotrienes, 5-oxo-6,8,11,14-eicosatetraenoic acid, lipoxins and epoxyeicosatrienoic acids), EPA (E-series resolvins), and DHA (D-series resolvins, protectins and maresins).

biochemistry & molecular biology,nutrition & dietetics
Myeloid ALX/FPR2 regulates vascularization following tissue injury

Brian E. Sansbury,Xiaofeng Li,Blenda Wong,Andreas Patsalos,Nikolas Giannakis,Michael J. Zhang,Laszlo Nagy,Matthew Spite

DOI: https://doi.org/10.1073/pnas.1918163117

IF: 11.1

2020-06-08

Proceedings of the National Academy of Sciences

Abstract:Significance Ischemia is a major cause of morbidity and mortality and can lead to progressive tissue dysfunction. Ischemia promotes an inflammatory response that must be resolved to facilitate tissue repair and revascularization. Resolvins are lipid mediators that promote resolution of inflammation in part via specific receptors on macrophages. This study identifies that resolvin D1 is generated during tissue ischemia and induces a pro-revascularization phenotype in macrophages via its receptor, ALX/FPR2, leading to enhanced tissue perfusion. Because impaired resolution of inflammation in chronic inflammatory diseases is associated with altered tissue vascularization, these results could inform therapeutic approaches to improving tissue perfusion.
New endogenous anti-inflammatory and proresolving lipid mediators: implications for rheumatic diseases

Stephanie Yacoubian,Charles N Serhan

DOI: https://doi.org/10.1038/ncprheum0616

2007-10-01

Nature Clinical Practice Rheumatology

Abstract:Lipoxins and aspirin-triggered lipoxins have emerged as important factors in anti-inflammatory and proresolution pathways, the absence of which might cause chronic inflammation. The newly discovered resolvins and protectins, derived from omega-3 polyunsaturated fatty acids, are also potent locally acting agonists of endogenous anti-inflammation, and promote resolution. The functions of these lipid mediators, and their potential beneficial use in rheumatoid arthritis, are outlined in this Review.
Wide-band circularly polarized antenna for dual-band GPS receiver

Y.-Q Zhang,L. Yang,S. Gong,X. Li

DOI: https://doi.org/10.1109/ISAPE.2012.6408708

2012-10-01

Abstract:In this letter, the design of a wide-band circularly polarized microstrip antenna with gain of more than 8dB is introduced. This antenna is designed for the global positioning satellite operations at 1227 MHz(L2) and 1575 MHz(L1). It has an advantage of a much wider band in both VSWR and 3dB axial-ratio compared with single-feed GPS antennas. Details of design, simulated results of this GPS antenna are presented and discussed. The results confirm the validity of this design which meet the requirement of GPS application.
Formylpeptide receptor 2: Nomenclature, structure, signalling and translational perspectives: IUPHAR review 35

Cheng Xue Qin,Lucy V Norling,Elizabeth A Vecchio,Eoin P Brennan,Lauren T May,Denise Wootten,Catherine Godson,Mauro Perretti,Rebecca H Ritchie

DOI: https://doi.org/10.1111/bph.15919

Abstract:We discuss the fascinating pharmacology of formylpeptide receptor 2 (FPR2; often referred to as FPR2/ALX since it binds lipoxin A4 ). Initially identified as a low-affinity 'relative' of FPR1, FPR2 presents complex and diverse biology. For instance, it is activated by several classes of agonists (from peptides to proteins and lipid mediators) and displays diverse expression patterns on myeloid cells as well as epithelial cells and endothelial cells, to name a few. Over the last decade, the pharmacology of FPR2 has progressed from being considered a weak chemotactic receptor to a master-regulator of the resolution of inflammation, the second phase of the acute inflammatory response. We propose that exploitation of the biology of FPR2 offers innovative ways to rectify chronic inflammatory states and represents a viable avenue to develop novel therapies. Recent elucidation of FPR2 structure will facilitate development of the anti-inflammatory and pro-resolving drugs of next decade.
Proresolving Lipid Mediators in the Respiratory System

Charles N Serhan,Bruce D Levy

DOI: https://doi.org/10.1146/annurev-physiol-020924-033209

2024-09-20

Abstract:Lung inflammation, infection, and injury can lead to critical illness and death. The current means to pharmacologically treat excessive uncontrolled lung inflammation needs improvement because many treatments are or will become immunosuppressive. The inflammatory response evolved to protect the host from microbes, injury, and environmental insults. This response brings phagocytes from the bloodstream to the tissue site to phagocytize and neutralize bacterial invaders and enables airway antimicrobial functions. This physiologic response is ideally self-limited with initiation and resolution phases. Polyunsaturated essential fatty acids are precursors to potent molecules that govern both phases. In the initiation phase, arachidonic acid is converted to prostaglandins and leukotrienes that activate leukocytes to transmigrate from postcapillary venules. The omega-3 fatty acids (e.g., DHA and EPA) are precursors to resolvins, protectins, and maresins, which are families of chemically distinct mediators with potent functions in resolution of acute and chronic inflammation in the respiratory system.
Epigenetic regulation of the formyl peptide receptor 2 gene

Felice Simiele,Antonio Recchiuti,Sara Patruno,Roberto Plebani,Anna Maria Pierdomenico,Marilina Codagnone,Mario Romano

DOI: https://doi.org/10.1016/j.bbagrm.2016.07.007

Abstract:Lipoxin (LX) A4, a main stop signal of inflammation, exerts potent bioactions by activating a specific G protein-coupled receptor, termed formyl peptide receptor 2 and recently renamed ALX/FPR2. Knowledge of the regulatory mechanisms that drive ALX/FPR2 gene expression is key for the development of innovative anti-inflammatory pharmacology. Here, we examined chromatin patterns of the ALX/FPR2 gene. We report that in MDA-MB231 breast cancer cells, the ALX/FPR2 gene undergoes epigenetic silencing characterized by low acetylation at lysine 27 and trimethylation at lysine 4, associated with high methylation at lysine 27 of histone 3. This pattern, which is consistent with transcriptionally inaccessible chromatin leading to low ALX/FPR2 mRNA and protein expression, is reversed in polymorphonuclear leukocytes that express high ALX/FPR2 levels. Activation of p300 histone acetyltransferase and inhibition of DNA methyltransferase restored chromatin accessibility and significantly increased ALX/FPR2 mRNA transcription and protein levels in MDA-MB231 cells, as well as in pulmonary artery endothelial cells. In both cells types, changes in the histone acetylation/methylation status enhanced ALX/FPR2 signaling in response to LXA4. Collectively, these results uncover unappreciated epigenetic regulation of ALX/FPR2 expression that can be exploited for innovative approaches to inflammatory disorders.
Lipid mediators in neutrophil biology: inflammation, resolution and beyond

Anita Ghodsi,Andres Hidalgo,Stephania Libreros

DOI: https://doi.org/10.1097/moh.0000000000000822

2024-05-30

Current Opinion in Hematology

Abstract:Purpose of review Acute inflammation is the body's first defense in response to pathogens or injury. Failure to efficiently resolve the inflammatory insult can severely affect tissue homeostasis, leading to chronic inflammation. Neutrophils play a pivotal role in eradicating infectious pathogens, orchestrating the initiation and resolution of acute inflammation, and maintaining physiological functions. The resolution of inflammation is a highly orchestrated biochemical process, partially modulated by a novel class of endogenous lipid mediators known as specialized pro-resolving mediators (SPMs). SPMs mediate their potent bioactions via activating specific cell-surface G protein-coupled receptors (GPCR). Recent findings This review focuses on recent advances in understanding the multifaceted functions of SPMs, detailing their roles in expediting neutrophil apoptosis, promoting clearance by macrophages, regulating their excessive infiltration at inflammation sites, orchestrating bone marrow deployment, also enhances neutrophil phagocytosis and tissue repair mechanisms under both physiological and pathological conditions. We also focus on the novel role of SPMs in regulating bone marrow neutrophil functions, differentiation, and highlight open questions about SPMs' functions in neutrophil heterogeneity. Summary SPMs play a pivotal role in mitigating excessive neutrophil infiltration and hyperactivity within pathological milieus, notably in conditions such as sepsis, cardiovascular disease, ischemic events, and cancer. This significant function highlights SPMs as promising therapeutic agents in the management of both acute and chronic inflammatory disorders.

hematology
Diagnostic accuracy of ultrasound for assessment of hemophilic arthropathy: MRI correlation.

A. Doria,S. Keshava,Arun Mohanta,J. Jarrín,V. Blanchette,A. Srivastava,R. Moineddin,M. Kavitha,P. Hilliard,P. Poonnoose,S. Gibikote

DOI: https://doi.org/10.2214/AJR.14.12501

2015-02-25

Abstract:OBJECTIVE. The purpose of this article is to assess the reliability of interpretation of ultrasound findings according to data blinding in maturing hemophilic joints and to determine the diagnostic accuracy of ultrasound compared with MRI for assessing joint components. SUBJECTS AND METHODS. Ankles (n = 34) or knees (n = 25) of boys with hemophilia or von Willebrand disease (median age, 13 years; range, 5-17 years) were imaged by ultrasound, MRI, and radiography in two centers (Toronto, Canada, and Vellore, India). Ultrasound scans were performed by two operators (one blinded and one unblinded to MRI data) and were reviewed by four reviewers who were unblinded to corresponding MRI findings according to a proposed 0- to 14-item scale that matches 14 of 17 items of the corresponding MRI scale. MRI examinations were independently reviewed by two readers. RESULTS. When data were acquired by radiologists, ultrasound was highly reliable for assessing soft-tissue changes (intraclass correlation coefficient [ICC], 0.98 for ankles and 0.97 for knees) and substantially to highly reliable for assessing osteochondral changes (ICC, 0.61 for ankles and 0.89 for knees). Ultrasound was highly sensitive (> 92%) for assessing synovial hypertrophy and hemosiderin in both ankles and knees but had borderline sensitivity for detecting small amounts of fluid in ankles (70%) in contrast to knees (93%) and variable sensitivity for evaluating osteochondral abnormalities (sensitivity range, 86-100% for ankles and 12-100% for knees). CONCLUSION. If it is performed by experienced radiologists using a standardized protocol, ultrasound is highly reliable for assessing soft-tissue abnormalities of ankles and knees and substantially to highly reliable for assessing osteochondral changes in these joints.
New Advances in Targeting the Resolution of Inflammation: Implications for Specialized Pro-Resolving Mediator GPCR Drug Discovery

Julia Park,Christopher J Langmead,Darren M Riddy

DOI: https://doi.org/10.1021/acsptsci.9b00075

2020-01-20

Abstract:Chronic inflammation is a component of numerous diseases including autoimmune, metabolic, neurodegenerative, and cancer. The discovery and characterization of specialized pro-resolving mediators (SPMs) critical to the resolution of inflammation, and their cognate G protein-coupled receptors (GPCRs) has led to a significant increase in the understanding of this physiological process. Approximately 20 ligands, including lipoxins, resolvins, maresins, and protectins, and 6 receptors (FPR2/ALX, GPR32, GPR18, chemerin1, BLT1, and GPR37) have been identified highlighting the complex and multilayered nature of resolution. Therapeutic efforts in targeting these receptors have proved challenging, with very few ligands apparently progressing through to preclinical or clinical development. To date, some knowledge gaps remain in the understanding of how the activation of these receptors, and their downstream signaling, results in efficient resolution via apoptosis, phagocytosis, and efferocytosis of polymorphonuclear leukocytes (mainly neutrophils) and macrophages. SPMs bind and activate multiple receptors (ligand poly-pharmacology), while most receptors are activated by multiple ligands (receptor pleiotropy). In addition, allosteric binding sites have been identified signifying the capacity of more than one ligand to bind simultaneously. These fundamental characteristics of SPM receptors enable alternative targeting strategies to be considered, including biased signaling and allosteric modulation. This review describes those ligands and receptors involved in the resolution of inflammation, and highlights the most recent clinical trial results. Furthermore, we describe alternative mechanisms by which these SPM receptors could be targeted, paving the way for the identification of new therapeutics, perhaps with greater efficacy and fidelity.
Resolvins, Specialized Proresolving Lipid Mediators, and Their Potential Roles in Metabolic Diseases

Matthew Spite,Joan Clària,Charles N. Serhan,Charles N. Serhan

DOI: https://doi.org/10.1016/j.cmet.2013.10.006

IF: 29

2014-01-01

Cell Metabolism

Abstract:Inflammation is associated with the development of diseases characterized by altered nutrient metabolism. Although an acute inflammatory response is host-protective and normally self-limited, chronic low-grade inflammation associated with metabolic diseases is sustained and detrimental. The resolution of inflammation involves the termination of neutrophil recruitment, counterregulation of proinflammatory mediators, stimulation of macrophage-mediated clearance, and tissue remodeling. Specialized proresolving lipid mediators (SPMs)-resolvins, protectins, and maresins-are novel autacoids that resolve inflammation, protect organs, and stimulate tissue regeneration. Here, we review evidence that the failure of resolution programs contributes to metabolic diseases and that SPMs may play pivotal roles in their resolution.

cell biology,endocrinology & metabolism

Palladium-Zeolite nanofiber as an effective recyclable catalyst membrane for water treatment.

Antagonism of meta-chlorophenylpiperazine-induced inhibition of exploratory activity in an emergence procedure, the open field test, in rats

Pro-resolving lipid mediators are leads for resolution physiology

Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus

Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators

Nutritional modulation of the gut microbiota and immune system in preterm neonates susceptible to necrotizing enterocolitis.

Development of synthetic lipoxin-A4 mimetics (sLXms): New avenues in the treatment of cardio-metabolic diseases

Anti-inflammatory lipid mediators and insights into the resolution of inflammation

A signaling network map of Lipoxin (LXA4): an anti-inflammatory molecule

Resolution of Inflammation after Skeletal Muscle Ischemia–Reperfusion Injury: A Focus on the Lipid Mediators Lipoxins, Resolvins, Protectins and Maresins

Old and new generation lipid mediators in acute inflammation and resolution

Myeloid ALX/FPR2 regulates vascularization following tissue injury

New endogenous anti-inflammatory and proresolving lipid mediators: implications for rheumatic diseases

Wide-band circularly polarized antenna for dual-band GPS receiver

Formylpeptide receptor 2: Nomenclature, structure, signalling and translational perspectives: IUPHAR review 35

Proresolving Lipid Mediators in the Respiratory System

Epigenetic regulation of the formyl peptide receptor 2 gene

Lipid mediators in neutrophil biology: inflammation, resolution and beyond

Diagnostic accuracy of ultrasound for assessment of hemophilic arthropathy: MRI correlation.

New Advances in Targeting the Resolution of Inflammation: Implications for Specialized Pro-Resolving Mediator GPCR Drug Discovery

Resolvins, Specialized Proresolving Lipid Mediators, and Their Potential Roles in Metabolic Diseases